Jim Cramer: The Strength in Pharma, Health Care and Real Estate Is Transient

The seemingly terrific rationales for strength in these economically sensitive sectors seem glib until the bigger global economic issues get resolved.

Biogen, Eisai Aim to Bring Their Alzheimer Drug to Market

Real Money reveals the crucial component Biogen got right in this trial and what it plans for the drug next.

Biotech Stocks Rally on Biogen's Landmark Test

Investors might be finally recognizing the hidden value of the firms' drug research and development.

3 Stocks to Buy to Steer Clear of Trade Wars: Market Recon

The U.S. and China will eventually negotiate, but until then, here is how to play it.

Why Travel Stocks Could Be in Trouble Just as Vacation Season Begins

The latest data from Bureau of Economic Analysis is a bad sign for the travel industry.

Don't Hitch Your Wagon to Wells Fargo Just Yet

WFC could well pull back and fill the price gap in the days ahead.

FDA Approval Puts GW Pharma, Three Other Cannabis-Related Names in the Spotlight

The milestone approval of Epidiolex bodes well for cannabis-based drug stocks GW Pharma, Nemus, Zynerba and Insys.

Tackling Trade Is a Dangerous Sport: Market Recon

Technology took it on the chin with Trump's China trade talk.

Jim Cramer: Trump Is Betting That China Is a Paper Tiger

Our GLUM Index stocks will be hit hard by this trade war.

How to Trade During a Global Trade War: Market Recon

It is going to be a rough day, but we can adapt, and win.